A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Assess the safety and tolerability of VS-4718 in subjects with metastatic non-hematologic malignancies
Serious Adverse events, Adverse events and their frequency, duration and severity, physical examination, laboratory parameters, vital signs and ECGs as determined based on CTCAE (Common Toxicity Criteria for Adverse Effects) V4.03. A Safety monitoring committee will review safety information.
Expected average of 12 weeks from start of treatment to end of treatment
Mitchell Keegan, Ph.D.
United States: Food and Drug Administration
|Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center||Los Angeles, California 90048|